[Minutes, Advisory Committee to the Director GP-160 Meeting (1992: Bethesda, Maryland)]

95

1 doing that?
2 And, secondly, as the information becomes
3 available, how do we design this critical path? Can
4 we take that information and really put it in a
5 meaningful path that all of us can agree on?
6 Well, finally, let me make my own comments
7 with regard to post-exposure vaccination, which we
8 have been discussing today. Clearly, there are a
9 number of challenges here. You have heard some of
10 these points already expressed, and I won't belabor
11 them.
12 The issue of precedent is important. The
13 issue of how to obtain surrogate markers is important.
14 I'm impressed with the fact that there are plenty of
15 ongoing and planned studies that should be evaluated
16 before making decisions about going on for large-scale
17 trials.
18 Some of you may prefer that as a question,
19 rather than a statement. In my opinion, there is a
20 lot of data to sift through even here that may guide
21 us into the best way to approach large-scale studies.
22 And, finally, what I would like to say is
NEAL R. GROSS
COURT REPORTERS AND TRANSCRIBERS
1323 RHODE ISLAND AVENUE, NW.
[phone] WASHINGTON, D.C. 20005 [phone]